Publication
Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study.
Journal Paper/Review - Mar 1, 2022
Benkert Pascal, Meier Stephanie, Schaedelin Sabine, Manouchehrinia Ali, Yaldizli Ozgür, Maceski Aleksandra, Oechtering Johanna, Achtnichts Lutz, Conen David, Derfuss Tobias, Lalive Patrice H, Mueller Christian, Müller Stefanie, Naegelin Yvonne, Oksenberg Jorge R, Pot Caroline, Salmen Anke, Willemse Eline, Kockum Ingrid, Blennow Kaj, Zetterberg Henrik, Gobbi Claudio, Kappos Ludwig, Wiendl Heinz, Berger Klaus, Sormani Maria Pia, Granziera Cristina, Piehl Fredrik, Leppert David, Kuhle Jens
Units
PubMed
Doi
Contact
Citation
Type
Journal
Publication Date
Issn Electronic
Pages
Brief description/objective
Serum neurofilament light chain (sNfL) is a biomarker of neuronal damage that is used not only to monitor disease activity and response to drugs and to prognosticate disease course in people with multiple sclerosis on the group level. The absence of representative reference values to correct for physiological age-dependent increases in sNfL has limited the diagnostic use of this biomarker at an individual level. We aimed to assess the applicability of sNfL for identification of people at risk for future disease activity by establishing a reference database to derive reference values corrected for age and body-mass index (BMI). Furthermore, we used the reference database to test the suitability of sNfL as an endpoint for group-level comparison of effectiveness across disease-modifying therapies.